Azevedo, R. S., Short, N., Bataller, A., Daver, N., Kadia, T., DiNardo, C., Bazinet, A., Issa, G., Jabbour, E., Borthakur, G., Senapati, J., Jen, W., Chien, K., Kornblau, S., Tippett, D., Yilmaz, M., Montalban-Bravo, G., Kantarjian, H., Garcia-Manero, G., Ravandi, F. (2025). Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome. Blood. https://doi.org/10.1182/blood-2025-997